The Patented Medicine Prices Review Board has released its seventh edition CompassRX report, Annual Public Drug Plan Expenditure Report for 2019/20. The report was prepared as part of the National Prescription Drug Utilization Information System, and examines public drug plan expenditures in Canada, including analysing the main factors that drive annual changes in prescription drug expenditures.

For further information on this topic please contact Urszula Wojtyra at Smart & Biggar by telephone (+1 416 593 5514) or email ([email protected]). The Smart & Biggar website can be accessed at